Identification of Potential Inhibitors to Targeting Matrix Metalloproteinase‐9 (MMP‐9) for Keratoconus Therapy
ChemistrySelect · 2026-11 · 11 (43)
DOI: 10.1002/slct.75117 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 17.11.2026. Verfasst von Mukesh Kumar und 5 weiteren Autor:innen. Die Arbeit nennt 57 Literaturangaben.
Abstract (Originalsprache)
Keratoconus is an advanced ectatic corneal disease characterized by thinning of corneal stroma and conical ectasia resulting in vision loss. Imbalance of corneal extracellular matrix homeostasis, mediated by excessive activity of matrix metalloproteinase‐9 (MMP‐9), is a key contributor to disease progression. Thus, MMP‐9 inhibition is a promising therapeutic approach for keratoconus. For this structure‐based computational modelling method was used in this study to discover novel small molecule inhibitors of MMP‐9. Structure‐based virtual screening of 25,000 compounds was executed to find novel inhibitors of MMP‐9. Initial docking filtered twenty compounds with strong binding affinities (−10 to −11 kcal/mol). Further, shortlisted molecules were additionally assessed using molecular dynamics simulations and MM/GBSA free energy evaluation to validate the stability of the protein–ligand complexes and their thermodynamic binding free energy. Amongst them, compounds 36 and 3223 exhibited constant binding in the catalytic pocket of MMP‐9 during the simulation. Both ligands preserved constant interaction with crucial residues and confirmed promising binding free energies, representing decent thermodynamic stability. These conclusions advocate that compounds 36 and 3223 may work as encouraging top lead molecules against MMP‐9. Though, experimental validations are required to endorse their therapeutic significance. Keratoconus, is a conical protrusion of the cornea due to thinning of stroma which leads to visual distortion. It mainly cause by increased of the pro‐inflammatory cytokines, IL‐1β and TNF‐α, induce NF‐κB which elevates the MMP‐9 for escalating collagen type II degradation. Computational analysis suggest compounds 36 and 3223 may inhibit MMP‐9 activity, maintain corneal extracellular matrix integrity, and decrease disease progression.
Zitieren
APA
Kumar, M., Suman, S., Trivedi, R., Kumar, P., Rao, D. R., & Shukla, P. K. (2026). Identification of Potential Inhibitors to Targeting Matrix Metalloproteinase‐9 (MMP‐9) for Keratoconus Therapy. ChemistrySelect, 11(43). https://doi.org/10.1002/slct.75117
Vancouver
Kumar M, Suman S, Trivedi R, Kumar P, Rao DR, Shukla PK. Identification of Potential Inhibitors to Targeting Matrix Metalloproteinase‐9 (MMP‐9) for Keratoconus Therapy. ChemistrySelect. 2026;11(43). doi:10.1002/slct.75117
BibTeX
@article{Kumar2026,
author = {Kumar, Mukesh and Suman, Saurabh and Trivedi, Rajeev and Kumar, Pawan and Rao, Dinesh R. and Shukla, Prakash Kumar},
title = {Identification of Potential Inhibitors to Targeting Matrix Metalloproteinase‐9 (MMP‐9) for Keratoconus Therapy},
journal = {ChemistrySelect},
year = {2026},
volume = {11},
number = {43},
doi = {10.1002/slct.75117}
}
EUVIMED